Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HLCS | P50747 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30094823 | 0.90 | HLCS (0.64) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2536441 | 0.89 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31364275 | 0.89 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| Hydrochloric Acid SCHEMBL3417755 | 0.88 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3790437 | 0.87 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL693036 | 0.87 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL30058455 | 0.86 | TDP1 (0.64) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1033634 | 0.85 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28346778 | 0.85 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29460477 | 0.85 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117706083-A | Chemiluminescent immunoassay kit, preparation method and detection method thereof | 深圳市卓润生物科技有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-113105526-B | Polypeptide, application thereof, probe comprising polypeptide and kit | 北京鲲达宇科技有限公司 | 2022-04-26 | — | — | CN | claimed |
| EP-4745152-A2 | PEPTIDES BINDING TO BFL-1 | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3341008-B1 | PEPTIDES BINDING TO BFL-1 | DANA FARBER CANCER INST INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570698-B2 | Stabilized peptides for covalent binding to target protein | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12552873-B2 | Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | VERSEAU THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661892-A1 | TNF-ALPHA BINDING AGENTS AND METHODS OF USING THE SAME | Navigen, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12466853-B2 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-RE50594-E1 | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-09-23 | — | — | US | disclosed |
| US-12398179-B2 | Nanomolar peptides and derivatives to differentially modulate ephrin receptors | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025151826-A1 | DETERMINATION OF PROTEIN INFORMATION BY RECODING AMINO ACID POLYMERS INTO DNA POLYMERS WITH METADATA TAGGING | ABRUS BIO, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2023028603-A2 | ENGINEERED COMPOSITIONS | HUMABS BIOMED SA (CH) | 2023-03-02 | — | — | WO | disclosed |
| US-20220396632-A1 | ANTI-PSGL-1 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFALMMATORY PHENOTYPES AND USES THEREOF | VERSEAU THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| CN-113024640-B | Epitope peptide antigen detection neutralizing antibody kit based on screening of binding domain of RBD and ACE2 receptor of new coronavirus | 广州中医药大学顺德医院(佛山市顺德区中医院) | 2022-07-26 | — | — | CN | disclosed |
| US-20220213146-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. | 2022-07-07 | — | — | US | disclosed |
| WO-2022115486-A1 | ANTIBODIES THAT BIND TO MULTIPLE BETACORONAVIRUSES | Vir Biotechnology, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220144893-A1 | NANOMOLAR PEPTIDES AND DERIVATIVES TO DIFFERENTIALLY MODULATE EPHRIN RECEPTORS | Sanford Burnham Prebys Medical Discovery Institute | 2022-05-12 | — | — | US | disclosed |
| CN-113388025-B | Polypeptide, composition and application thereof | 北京鲲达宇科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113105526-B | Polypeptide, application thereof, probe comprising polypeptide and kit | 北京鲲达宇科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022056473-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466853-B2 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | MCL1, BCL2L1, BCL2L11 | TDP1 220/4885MEN1 1146/4885ABL1 1015/4885 |
| US-12570698-B2 | Stabilized peptides for covalent binding to target protein | STUB1, JMJD7, PTMS | TDP1 3504/4885MEN1 3215/4885ABL1 2191/4885 |
| US-20220213146-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | HSPBP1, HSPA8, PTMS | TDP1 3688/4885MEN1 2924/4885ABL1 2230/4885 |
| US-12552873-B2 | Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | CD209, CSF3R, CHI3L1 | TDP1 3965/4885MEN1 3559/4885ABL1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.